May 13, 2020
|
MacroGenics Announces Preliminary Clinical Results from MGD013 and MGC018 to be Presented at the ASCO Annual Meeting
|
|
May 05, 2020
|
MacroGenics Provides Update on Corporate Progress and First Quarter 2020 Financial Results
|
|
Apr 29, 2020
|
MacroGenics Announces Presentations at the 2020 ASCO Annual Meeting
|
|
Apr 28, 2020
|
MacroGenics to Host its Annual Meeting of Stockholders in Virtual Format
|
|
Apr 28, 2020
|
MacroGenics Announces Date of First Quarter 2020 Financial Results Conference Call
|
|
Apr 27, 2020
|
MacroGenics Announces Presentation of Flotetuzumab Translational Data at the 2020 AACR Annual Meeting
|
|
Mar 04, 2020
|
MacroGenics Announces Departure of Chief Medical Officer
|
|
Feb 27, 2020
|
MacroGenics to Participate in Upcoming Investor Conferences
|
|
Feb 25, 2020
|
MacroGenics Provides Update on Corporate Progress and 2019 Financial Results
|
|
Feb 13, 2020
|
MacroGenics Announces Date of Fourth Quarter and Full Year 2019 Financial Results Conference Call
|
|
Feb 10, 2020
|
MacroGenics to Participate in Upcoming Investor Conferences
|
|
Jan 13, 2020
|
MacroGenics to Present at the J.P. Morgan Healthcare Conference
|
|
Jan 09, 2020
|
MacroGenics Outlines Corporate Priorities for 2020
|
|
Dec 19, 2019
|
MacroGenics Announces Submission of Margetuximab Biologics License Application to U.S. FDA
|
|
Dec 11, 2019
|
MacroGenics Presents Results from the SOPHIA Study of Margetuximab in Patients with HER2-Positive Metastatic Breast Cancer at the San Antonio Breast Cancer Symposium
|
|
Dec 09, 2019
|
MacroGenics Presents Flotetuzumab Data in Patients with Primary Induction Failure and Early Relapsed Acute Myeloid Leukemia at the 2019 ASH Annual Meeting
|
|
Dec 02, 2019
|
MacroGenics to Participate in the Evercore ISI HealthCONx Conference
|
|
Nov 07, 2019
|
MacroGenics to Participate in Upcoming Investor Conferences
|
|
Nov 06, 2019
|
MacroGenics Provides Update on Corporate Progress and Third Quarter 2019 Financial Results
|
|
Nov 06, 2019
|
MacroGenics Announces Flotetuzumab Presentations at the ASH Annual Meeting 2019
|
|
Oct 30, 2019
|
MacroGenics Announces Date of Third Quarter 2019 Financial Results Conference Call
|
|
Oct 25, 2019
|
MacroGenics Announces Initiation of Phase 2/3 MAHOGANY Study of Margetuximab in Gastric or Gastroesophageal Junction Cancer
|
|
Oct 22, 2019
|
MacroGenics Announces Second Interim Overall Survival Data from Phase 3 SOPHIA Study of Margetuximab in Patients with HER2-Positive Metastatic Breast Cancer
|
|
Sep 30, 2019
|
MacroGenics Presents Margetuximab Data in Gastroesophageal Cancer at the ESMO 2019 Congress
|
|
Sep 26, 2019
|
MacroGenics to Participate in Cantor Global Healthcare Conference
|
|